Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy  by Sijpkens, Yvo. W. et al.
Kidney International, Vol. 65 (2004), pp. 2409–2418
Immunologic risk factors and glomerular C4d deposits in chronic
transplant glomerulopathy
YVO W. SIJPKENS, SIMONE A. JOOSTEN, MAN-CHI WONG, FRIEDO W. DEKKER, HALLGRIMUR
BENEDIKTSSON, INGEBORG M. BAJEMA, JAN A. BRUIJN, and LEENDERT C. PAUL
Department of Nephrology, Department of Epidemiology and Department of Pathology, Leiden University Medical Center, Leiden,
The Netherlands; and Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
Immunologic risk factors and glomerular C4d deposits in
chronic transplant glomerulopathy.
Background. Chronic transplant glomerulopathy is an un-
common cause of chronic transplant dysfunction of unknown
pathogenesis. We evaluated the epidemiologic, clinical, and his-
tologic features of chronic transplant glomerulopathy. To deter-
mine the possible contribution of humoral immune responses,
we assessed glomerular deposition of C4d.
Methods. From a cohort of 1111 kidney transplants (1983
to 2001) with at least 6 months of graft function, we identi-
fied 18 cases with chronic transplant glomerulopathy (1.6%)
showing double contours of the glomerular basement mem-
brane (GBM) on light microscopy. To assess the risk factors, this
group was compared with 739 patients with stable function using
multivariate Cox regression analysis. Paraffin sections of 11/18
biopsies were stained with polyclonal C4d antibodies. Sera of
13/18 patients could be tested for antidonor human leukocyte
antigen (HLA) antibodies by enzyme-linked immunosorbent
assay (ELISA). Patients with chronic allograft nephropathy
without chronic transplant glomerulopathy or predominant cy-
closporine nephrotoxicity were used as controls.
Results. Chronic transplant glomerulopathy was diagnosed
at a median of 8.3 (range 2.6–12.5) years posttransplantation.
Panel reactive antibodies at time of transplantation, RR 1.23
(1.05–1.45) per 10% increase, and late acute rejection episodes,
RR 7.6 (1.8–31.7), were independently associated with chronic
transplant glomerulopathy. We found glomerular C4d deposits
in 10/11 biopsies showing chronic transplant glomerulopathy
and in only 2/13 controls. Peritubular capillary C4d deposits and
donor-specific anti-HLA antibodies were demonstrated in 4 and
3 of the 10 patients with glomerular C4d deposits, respectively.
Conclusion. Presensitization and late acute rejection
episodes were the risk factors identified. Glomerular C4d de-
posits suggest that chronic transplant glomerulopathy emerges
from in situ humoral rejection. Chronic transplant glomeru-
lopathy should be considered as a manifestation of immune-
mediated injury.
Key words: kidney transplantation, chronic rejection, transplant
glomerulopathy, risk factors, C4d.
Received for publication May 5, 2003
and in revised form September 9, 2003, and December 10, 2003
Accepted for publication January 8, 2004
C© 2004 by the International Society of Nephrology
Chronic transplant glomerulopathy emerges in ap-
proximately 5% to 15% of transplants with chronic re-
jection [1–3], and is characterized by reduplication of the
glomerular basement membrane (GBM) in the absence
of de novo or recurrent glomerulonephritis [2]. Its ex-
tent is used to grade the severity of this entity in the
Banff 97 classification [4]. Chronic transplant glomeru-
lopathy usually occurs in the background of chronic al-
lograft nephropathy (i.e., interstitial fibrosis and tubular
atrophy with or without fibrous intimal thickening of ar-
teries [4, 5]). Immunofluorescence microscopy is negative
or shows mesangial granular deposits of IgM with greater
intensity than C3 [1, 6]. Electron microscopy reveals redu-
plication of the GBM and subendothelial accumulation
of electron-lucent material, distinguishing chronic trans-
plant glomerulopathy from recurrent membranoprolif-
erative glomerulonephritis [6]. Marked reduplication of
peritubular capillary basement membranes is strongly
associated with chronic transplant glomerulopathy [7].
Acute transplant glomerulitis, characterized by mononu-
clear cell infiltrate and endothelial cell enlargement, may
precede chronic transplant glomerulopathy [1, 4, 8].
Recently, it has been suggested that allograft glomeru-
lopathy should be separated from chronic rejection, as its
pathogenesis is not understood [5]. Furthermore, a new
classification of renal allograft rejection incorporates cel-
lular and humoral mechanisms of injury [9, 10]. Chronic
transplant glomerulopathy has been associated with cir-
culating antidonor human leukocyte antigen (HLA)
antibodies and the deposition of the complement
split product C4d in peritubular capillaries, suggesting
antibody-mediated injury [11, 12]. Regele et al [13] pro-
duced a polyclonal anti-C4d antibody that, in contrast to
monoclonal antibodies, can be used on paraffin sections
and does not stain normal glomeruli. However, glomeru-
lar deposits of C4d could be detected in only a minority
of chronic transplant glomerulopathy biopsies [12].
The aim of the current study was to determine the
incidence, risk factors, clinical characteristics and prog-
nostic factors of chronic transplant glomerulopathy in
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comparison with chronic allograft nephropathy without
chronic transplant glomerulopathy. Furthermore, circu-
lating antidonor HLA antibodies and glomerular deposi-
tion of C4d were assessed to determine whether humoral
immunity is involved in the development of chronic trans-
plant glomerulopathy.
METHODS
Patients
All 1111 cadaveric (N = 832), living related kidney
(N = 163), and simultaneous kidney pancreas (N = 116)
transplants done at the Leiden University Medical Cen-
ter between January 1983 and January 2001 with at least
6 months of graft function were reviewed. There were 168
repeat transplants. Patients were followed to graft loss,
death, or January 1, 2002. The initial immunosuppressive
regimen consisted of prednisone and cyclosporine and/or
azathioprine. In 1996, Sandimmune was changed to
Neoral and mycophenolate mofetil was added as a third
baseline drug.
Histopathology
We reviewed the biopsies that were taken beyond
6 months posttransplantation for clinical indications, in-
cluding declining renal function or significant proteinuria.
Recurrent (N = 56) or de-novo glomerulonephritis (N =
11) and predominant cyclosporine toxicity (N = 53) were
excluded by clinical and histologic means. Cyclosporine
nephrotoxicity was characterized by arteriolar hyalinosis
and stabilization of renal function after dose reduction or
switch to mycophenolate [14].
In 130 cases the histology indicated a diagnosis of
chronic allograft nephropathy. All biopsies were reex-
amined and if transplant glomerulopathy was present,
sections were scored according to the Banff 97 schema
[4] by a single pathologist (H.B.). Eighteen patients met
the definition of chronic transplant glomerulopathy ac-
cording to the following criteria: (1) light microscopy
showing “double contours” of the GBM in at least 10%
of the most severely affected tuft [4]; (2) immunofluo-
rescence negative or showing scant depositions of IgM
with greater intensity than C3 [6]; and (3) recipient’s
original renal disease other than membranoproliferative
glomerulonephritis and absence of hepatitis C seroposi-
tivity at time of transplantation [6, 15]. Unfortunately, no
material was available to perform electron microscopy
on these biopsies.
Four patients had acute transplant glomerulitis de-
fined by mononuclear cell infiltration and endothelial cell
enlargement in the absence of double contours of the
GBM [4, 16]. Finally, 108 patients had chronic allograft
nephropathy without predominant clinical and histologic
signs of transplant glomerulopathy, cyclosporine nephro-
toxicity or recurrent disease.
Clinical data and antidonor HLA antibodies
Clinical information was obtained from hospital charts
and laboratory records. Donor and recipient variables as
well as transplant and clinical parameters were recorded
as shown in Table 1. We studied the impact of HLA mis-
matches as broad antigens and as cross-reactive groups
(CREG) of major histocompatibility complex (MHC)
class I [17]. The clinical parameters were obtained at the
time of biopsy and at the time of the minimal level of
proteinuria following biopsy. Finally, the last measured
serum creatinine was collected from all patients with a
functioning transplant until death or end of follow-up.
In 13/18 chronic transplant glomerulopathy patients,
sera were available at time of biopsy. The presence of
circulating antidonor HLA class I and class II antibodies
were assessed by enzyme-linked immunosorbent assay
(ELISA) and flow cytometer cross-match.
C4d staining
Eleven biopsies from 18 patients with chronic trans-
plant glomerulopathy and three of four biopsies show-
ing acute transplant glomerulitis were available for
immunohistochemistry. Fourteen patients with chronic
allograft nephropathy without glomerular lesions were
randomly selected as control. Polyclonal rabbit anti-
C4d antibody (Biomedica, Vienna, Austria), kindly pro-
vided by Heinz Regele, was used on paraffin sections
as recently described [12, 13]. In brief, 2 lm sections
were deparaffinized and endogenous peroxidase ac-
tivity was blocked with hydrogen peroxide. Antigen
retrieval was carried out by pressure-cooking for 10 min-
utes at 1 bar in citrate buffer (pH 6.0). After overnight
incubation with polyclonal anti-C4d antibody (1:250),
sections were incubated with horseradish peroxidase
(HRP)-conjugated goat antirabbit immunoglobulins ab-
sorbed for human IgG. Finally, sections were stained with
tyramid-fluorescein isothiocyanate (FITC). Glomerular
staining was considered positive if one or more glomeruli
showed C4d deposits in the capillary wall. Peritubular
capillary staining was scored positive if 25% or more of
the peritubular capillaries was strongly positive.
Study design and statistical analysis
Demographic and clinical data of patients with
chronic transplant glomerulopathy or chronic allograft
nephropathy were compared using the independent sam-
ples t test for continuous variables and chi-square test for
categorical variables. A P value<0.05 was considered sig-
nificant. The cumulative incidence of chronic transplant
glomerulopathy was determined by the ratio of cases and
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Table 1. Patient characteristics of chronic transplant glomerulopathy (CTG) and chronic allograft nephropathy (CAN)
CTG (N = 18) CAN (N = 108) P value
Recipient factors
Age years 40 ± 11 41 ± 12 0.70
Gender % female 39 34 0.71
Cigarette smoking % 47 49 0.91
Peak panel-reactive antibodies % 32 ± 29 29 ± 30 0.72
Current panel-reactive antibodies % 18 ± 30 12 ± 23 0.33
Donor factors
Age years 31 ± 15 41 ± 15 <0.01a
Gender % female 44 44 0.98
Transplant factors
Year 1983–1989/1990–1995/1996–2001 % 56/44/0 53/36/11 0.32
Living % 11 8 0.70
Pancreas % 11 6 0.48
Previous % 17 19 0.85
Cold ischemia time hours 25 ± 11 26 ± 11 0.79
Delayed graft function % 24 24 0.99
New immunosuppressive agents % 0 8 0.32
HLA CREG mismatches 1.3 ± 1.4 1.9 ± 1.8 0.16
HLA-A-B broad mismatches 1.4 ± 1.0 1.7 ± 1.9 0.51
HLA-DR broad mismatches 0.5 ± 0.7 0.5 ± 0.6 0.95
HLA-A-B-DR broad mismatches 1.9 ± 1.2 2.0 ± 1.5 0.70
Acute rejection episodes
Type (one/interstitial/vascular) % 33/33/28 23/49/21 0.59
Number (one/two/three or more) % 17/28/22 21/32/29 0.51
First (<2 month/>2 months) % 56/11 56/26 0.21
Last (<3 months/>3 months) % 50/17 34/47 0.04a
Characteristic at time of biopsy
Median time from transplant to biopsy years 8.3 (2.6–12.5) 2.0 (0.6–13.7) <0.01a
New immunosuppressive agents % 67 24 <0.01a
Serum creatinine lmol/L 254 ± 107 247 ± 96 0.78
Creatinine clearance mL/min 35 ± 17 37 ± 18 0.66
Serum albumin g/L 38 ± 6 40 ± 5 0.09
Serum cholesterol mmol/L 5.5 ± 1.1 6.3 ± 1.5 0.03a
Proteinuria g/24 hours 3.1 ± 3.4 1.8 ± 2.1 0.03a
Proteinuria: <0.5/0.5–2.0/>2.0 g/24 hours % 6/44/50 36/35/29 0.03a
Systolic blood pressure mm Hg 159 ± 17 150 ± 20 0.11
Diastolic blood pressure mm Hg 87 ± 10 89 ± 14 0.54
Number of antihypertensive drugs 2.4 ± 1.1 1.8 ± 1.1 0.01a
Minimum proteinuria g/24 hours 1.4 ± 2.1 1.0 ± 1.6 0.36
Systolic pressure at minimum proteinuria mm Hg 144 ± 19 147 ± 21 0.58
Diastolic pressure at minimum proteinuria mm Hg 85 ± 11 85 ± 12 0.88
Abbreviations are: HLA, human leukocyte antigen; CREG, cross-reactive group.
aP value < 0.05.
total number of patients in the cohort. The time between
transplantation and the diagnosis of chronic transplant
glomerulopathy and chronic allograft nephropathy was
compared using the Kaplan-Meier actuarial method.
To identify the risk factors of chronic transplant
glomerulopathy or chronic allograft nephropathy the
groups were compared with 739 patients with stable func-
tion defined as a last serum creatinine of less than 120%
compared to the value at 6 months posttransplantation.
The individual effect of the variables on the time to
biopsy, graft failure, or end of follow-up was evaluated
with the use of the Cox proportional hazard model. Sig-
nificant predictors (P < 0.05) in univariate analysis were
fitted into a multivariate model according to a forward
selection, likelihood ratio test.
To assess prognostic factors associated with graft fail-
ure, outcome was defined as return to dialysis or as a last
serum creatinine concentration of more than 150% com-
pared to the value at time of biopsy. Uni- and multivariate
Cox regressions were used to evaluate the relationship
between the biopsy variables and time between diagno-
sis and graft failure. Cumulative survival rates were com-
puted by the Kaplan-Meier method.
RESULTS
Clinical features of chronic transplant glomerulopathy
and chronic allograft nephropathy
Eighteen patients out of a cohort of 1111 trans-
plants developed chronic transplant glomerulopathy,
leading to a cumulative incidence of 1.6%. Chronic al-
lograft nephropathy without transplant glomerulopathy,
cyclosporine nephrotoxicity, or recurrent disease was
diagnosed in 108 patients (9.7%). Considering these
126 patients together, the percentage of chronic trans-
plant glomerulopathy in chronic allograft nephropathy
was 14%. Table 1 shows the clinical data of 18 patients
with chronic transplant glomerulopathy in comparison
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Fig. 1. Cumulative incidence. Chronic transplant glomerulopathy
(dashed line, N = 18) and chronic allograft nephropathy (solid line,
N = 108) on follow-up biopsies (P = 0.004, log rank test).
with 108 patients with chronic allograft nephropathy.
Donor age was significantly lower in the chronic trans-
plant glomerulopathy group. Mean peak and current
panel reactive antibodies were not significantly differ-
ent between the two groups. There was no difference
in the number or type of acute rejection episodes but
in the chronic transplant glomerulopathy group there
were significantly fewer acute rejection episodes beyond
3 months. In comparison with chronic allograft nephropa-
thy, biopsies showing chronic transplant glomerulopa-
thy were obtained later (Fig. 1). At the time of biopsy,
the immunosuppressive regimen in the chronic trans-
plant glomerulopathy patients was more often based on
Neoral, compared to the chronic allograft nephropathy
group. Patients with chronic transplant glomerulopathy
had a renal function comparable with chronic allograft
nephropathy, but on average more proteinuria. Four out
of 18 (22%) chronic transplant glomerulopathy patients
had nephrotic syndrome defined by proteinuria of more
than 3.5 g per day and an albumin level of less than
35 g/L, in contrast to five out of 111 (4%) cases with
chronic allograft nephropathy. Systolic blood pressure
was higher in chronic transplant glomerulopathy than in
chronic allograft nephropathy despite a higher number of
antihypertensive drugs. Graft survival plotted beginning
at 6 months after transplantation (Fig. 2A) and at time of
biopsy (Fig. 2B) was not significantly different between
the two groups.
Characteristics of chronic transplant glomerulopathy
The features and outcome of the patients with chronic
transplant glomerulopathy (1 to 18) are shown in Table 2.
Renal biopsies were performed because of chronic trans-
plant dysfunction; 16 patients had a decline in renal func-
tion defined as an increase in serum creatinine of more
than 20% compared to the serum creatinine at 6 months
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Fig. 2. Graft survival. (A) After transplantation of pa-
tients with chronic transplant glomerulopathy (dashed line,
N = 18) and chronic allograft nephropathy (solid line, N = 108)
(P = 0.11, log rank test). (B) After diagnosis of chronic trans-
plant glomerulopathy (dashed line, N = 18) and chronic allograft
nephropathy (solid line, N = 108) (P = 0.99, log rank test).
posttransplantation, and 16 had more than 1 g protein-
uria per day; hypertension (>140/90 mm Hg) was present
in 14 cases, despite antihypertensive medication. Eleven
biopsies were adequate and seven were marginal accord-
ing to the Banff 97 criteria (i.e., all specimens showed at
least seven glomeruli and one artery). The diagnosis of
chronic transplant glomerulopathy was based on the ex-
tent of double contours of the GBM in the most severely
affected glomerulus [5], which was present in 10% to 25%
of capillary loops in four, 26% to 50% in four and more
than 50% in 10 cases (Fig. 3). The degree of proteinuria
did not correlate with the level of glomerular damage
(Table 2). Seventeen out of 18 cases showed variable
increase in mesangial cellularity. Fibrous intimal thick-
ening of arteries was absent in three, mild in seven, mod-
erate in four, and severe in four cases. Chronic allograft
nephropathy, based on the extent of interstitial fibrosis
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Table 2. Characteristics and outcome of patients with chronic transplant glomerulopathy (CTG) (1 to 18) and acute transplant glomerulitis
(ATG) (19 to 22)
Chronic transplant dysfunction Follow-up
Banff 97 score
Time Creatinine Clearance P BP Time
Number Disease years lmol/L mL/min g/24 hours mm Hg G CG CV CAN years Outcome
1 ADPKD 2.6 234 25 5.2 180/105 3 3 0 2 4.3 Dialysis
2 DM I 2.8 475 16 15.2 175/80 2 2 1 2 2.9 Dialysis
3 GN 3.1 506 22 2.8 160/85 3 3 2 2 3.2 Dialysis
4 CIN 4.6 224 21 3.2 125/55 1 3 1 3 5.6 Decline†
5 ADPKD 4.7 217 31 0.2 180/95 2 1 1 1 10.0 Stable
6 DM I 5.2 406 15 1.0 145/90 2 2 3 1 5.8 Stable
7 Alport 5.7 153 44 3.6 160/100 2 3 2 1 8.0 Decline†
8 CIN 7.1 203 34 1.2 160/90 2 3 1 2 11.2 Stable
9 CIN 8.3 169 49 6.0 155/95 2 2 3 2 17.8 Dialysis
10 GN 8.4 112 85 4.8 160/90 2 3 0 2 12.5 Stable†
11 CIN 8.6 225 18 1.7 190/90 3 2 3 3 8.8 Stable
12 ADPKD 9.4 188 57 1.9 165/85 3 1 1 1 11.4 Stable
13 CIN 9.4 168 48 0.7 160/85 0 3 1 1 12.2 Dialysis
14 GN 9.7 250 41 2.0 140/85 3 3 3 2 10.6 Stable
15 HT 9.9 236 30 2.0 160/85 2 1 2 2 10.6 Dialysis
16 DM I 11.3 270 29 2.7 130/90 2 1 0 2 12.7 Decline
17 CIN 12.3 220 35 1.0 140/85 3 3 1 3 14.9 Stable
18 HT 12.5 313 24 1.2 170/80 3 3 2 2 13.8 Stable
19 DM II 0.6 154 38 11.2 155/95 2 0 3 1 1.6 Dialysis
20 GN 1.2 264 20 2.7 140/100 2 0 3 3 1.5 Dialysis
21 GN 1.9 447 16 7.6 170/95 3 0 3 1 2.1 Dialysis
22 HT 3.3 227 45 2.7 145/95 2 0 1 2 3.9 Dialysis
Abbreviations are: time, time since transplantation; ADPKD, autosomal-dominant polycystic kidney disease; DM I and II, diabetes mellitus type I and type II,
respectively; GN, glomerulonephritis; CIN, chronic interstitial nephritis; HT, hypertension; G, glomerulitis; CG, glomerulopathy; CV, fibrous intimal thickening; CAN,
chronic allograft nephropathy (grade); BP, blood pressure; P, proteinuria.
†Died.
and tubular atrophy, was graded I, II, and III in five,
ten, and three cases, respectively. Immunofluorescence
revealed IgM in peripheral capillary loops and mesangial
regions in ten patients and weaker reactions to C3, IgG,
and IgA in five, four, and three patients, respectively. Cir-
culating antidonor HLA antibodies at the time of biopsy
were found in 5/13 patients tested. These antibodies were
directed to class I, class II, and class I + II in, respectively,
one, three, and one cases. Six patients lost their grafts and
returned to dialysis. Three patients had graft failure de-
fined by a creatinine rise of more than 50% at the end
of follow-up. Renal function was stable in the other nine
patients.
Four patients (19 to 22) had evidence of acute trans-
plant glomerulitis (Table 2). The percentage panel-
reactive antibodies at time of transplantation was 17%,
32%, 5%, and 6%, respectively. The patients had either
two or three acute rejection episodes. Biopsies showing
acute transplant glomerulitis were obtained at 0.6, 1.2, 1.9,
and 3.3 years after transplantation. The biopsies showed
glomerular infiltration by neutrophils and endocapillary
proliferation. Extracapillary proliferation was present in
one patient (Fig. 3A). There were no signs of tubulitis
or vasculitis, but chronic vascular and tubulointerstitial
changes were present in two and four patients, respec-
tively. Antibodies to HLA class I + II of the donor were
present in one of the two patients with serum available.
Graft loss occurred in all patients, within 1 year after
diagnosis.
Risk factors of chronic transplant glomerulopathy
and chronic allograft nephropathy
The univariate effects of the various risk factors of
chronic transplant glomerulopathy or chronic allograft
nephropathy in comparison with patients with a stable
function are shown in Table 3. Multivariate Cox regres-
sion analysis revealed that current panel-reactive anti-
bodies (RR 1.23, 95% CI 1.05–1.45 per 10% increase,
P = 0.01) and last acute rejection episodes beyond
3 months (RR 7.6, 95% CI 1.8–31.7, P = 0.006)
were independently associated with chronic transplant
glomerulopathy.
Chronic allograft nephropathy was independently pre-
dicted by cigarette smoking (RR 1.80, 95% CI 1.21–2.67,
P = 0.004), peak panel-reactive antibodies (RR = 1.10,
95% CI 1.03–1.18 per 10% increase, P = 0.004), donor
age (RR 1.24, 95% CI 1.07–1.43, P = 0.009), Neoral and
mycophenolate mofetil based regimens (RR 0.46, 95%
CI 0.21–0.99, P = 0.05), and especially a last acute rejec-
tion episode beyond 3 months (RR 14.5, 95% CI 8.3–25.1,
P = 0.0001).
Glomerular and peritubular C4d staining
in transplant glomerulopathy
C4d stained positive in a segmental capillary pattern in
the glomeruli of 10/11 chronic transplant glomerulopa-
thy biopsies and in 3/3 biopsies showing acute transplant
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Fig. 3. Light microscopy (A to C) (silver staining) and immunofluorescence for C4d (D to F) on paraffin sections. (A and D) Transplant glomerulitis
with endo- and extracapillary proliferation and segmental capillary staining of C4d. (B and E) Chronic transplant glomerulopathy with reduplication
of the glomerular basement membrane (GBM) and capillary staining of C4d. (C and F) Chronic allograft nephropathy without glomerular lesions
and negative C4d staining.
glomerulitis. Figure 3 shows the light and immunofluo-
rescence microscopy of three biopsies with acute trans-
plant glomerulitis, chronic transplant glomerulopathy,
and chronic allograft nephropathy without glomerular
lesions, respectively. Patient 19 (Fig. 3A, D) had acute
transplant glomerulitis, consisting of extensive endo- and
extracapillary proliferation at 6 months posttransplanta-
tion (Table 2). Patient 11 (B/D) developed chronic trans-
plant glomerulopathy with reduplication of the GBM at
81/2 years. Panel C/E shows a normal glomerulus without
C4d deposits in the biopsy of a patient with chronic re-
jection at 4 years. Peritubular staining for C4d was also
positive in 4/10 chronic transplant glomerulopathy and
3/3 acute transplant glomerulitis cases with glomerular
C4d deposits. Antidonor HLA antibodies were detected
in 3/10 chronic transplant glomerulopathy and 1/2 acute
transplant glomerulitis cases. Glomerular and peritubular
C4d deposits were found in one of the 14 control patients
with chronic allograft nephropathy (P < 0.001 compared
to chronic transplant glomerulopathy patients, chi-square
test).
Factors predicting graft failure
Table 4 shows factors prognostic for graft failure or
loss of renal function in patients with chronic transplant
glomerulopathy and chronic allograft nephropathy. Graft
failure from chronic transplant glomerulopathy, occur-
ring in nine of the 18 patients, was independently corre-
lated with the lowest level of 24-hour proteinuria (RR =
2.21 per g/day, 95% CI 1.21–4.04, P = 0.01). Fifty-one pa-
tients in the chronic allograft nephropathy group (46%)
lost their graft and 16 (14%) had a rise of serum creati-
nine of more than 50% at the end of follow-up. Therefore,
67 patients (60%) experienced graft failure. This was
predicted by serum creatinine (RR 1.07, 1.04–1.10 per
10 lmol/L, P < 0.001) at time of diagnosis, lowest level of
proteinuria after biopsy (RR 1.55, 1.24–1.93 per g/day,
P < 0.001) and the associated systolic blood pressure
(RR 1.24, 1.06–1.45 per 10 mm Hg, P = 0.006) in mul-
tivariate analysis.
DISCUSSION
We studied the clinical and immunohistochemical char-
acteristics of 18 patients with chronic transplant glomeru-
lopathy. The cumulative incidence of chronic transplant
glomerulopathy was 1.6%, which is somewhat lower com-
pared to the incidence of 1.9% to 7% reported in other
series [1–3]. As biopsies are not invariably obtained in
patients with declining graft function, and chronic trans-
plant glomerulopathy has been reported in protocol biop-
sies the incidence may have been underestimated [18].
Chronic transplant glomerulopathy presents as chronic
transplant dysfunction in the cases biopsied, a clinical
syndrome consisting of an increased serum creatinine
concentration, elevated blood pressure, and protein-
uria. Diagnostic biopsies were performed later com-
pared with patients with chronic allograft nephropathy,
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Table 3. Univariate analysis of risk factors of chronic transplant glomerulopathy (CTG) and chronic allograft nephropathy (CAN) in comparison
with 739 patients with a stable function
CTG (N = 18) CAN (N = 108)
RR 95% CI RR 95% CI
Recipient factors
Age 10 years 0.83 0.57–1.23 0.83 0.71–0.97a
Gender female 1.17 0.45–3.03 1.20 0.81–1.77
Cigarette smoking 0.89 0.21–3.73 1.67 1.14–2.45a
Peak panel-reactive antibodies 10% 1.10 0.96–1.29 1.12 1.06–1.20a
Current panel-reactive antibodies 10% 1.20 1.02–1.40a 1.14 1.04–1.23a
Donor factors
Age 10 years 0.77 0.53–1.12 1.26 1.10–1.44a
Gender female 0.87 0.34–2.19 0.95 0.65–1.38
Transplant factors
Year 1990–1995 vs. 1983–1989 1.52 0.53–4.32 0.62 0.41–0.95a
Year 1996–2001 vs. 1983–1989 NA NA 0.37 0.20–0.70a
Living 0.66 0.15–2.88 0.52 0.26–1.02
Pancreas 2.50 0.56–11.3 0.70 0.33–1.51
Previous 1.13 0.33–3.91 1.43 0.88–2.32
Cold ischemic time hour 1.01 0.97–1.05 1.02 1.00–1.04a
Delayed graft function % 1.08 0.35–3.32 1.18 0.75–1.84
New immunosuppressive agents 0.04 0.00–85.3 0.30 0.15–0.63a
HLA CREG mismatches 0.93 0.66–1.30 1.12 1.00–1.26a
HLA-A-B mismatches 0.95 0.60–1.50 1.06 0.93–1.20
HLA-DR mismatches 1.70 0.54–2.52 0.95 0.69–1.30
HLA-A-B-DR mismatches 1.00 0.70–1.43 0.98 0.86–1.12
Acute rejection episodes
Interstitial 8.21 0.91–74.3 3.59 2.32–5.77a
Vascular 3.36 1.02–10.9a 3.60 2.04–6.34a
Number 1.63 1.07–2.98a 1.87 1.58–2.13a
First episode within 2 months 7.93 0.97–64.7 3.06 1.85–5.07a
First episode after 2 months 10.7 0.66–171 13.5 7.57–23.9a
Last episode within 3 months 7.34 0.88–61.2 1.97 1.15–3.39a
Last episode after 3 months 12.6 1.13–139a 16.4 9.72–27.6a
Abbreviations are: HLA, human leukocyte antigen; CREG, cross-reactive group; NA, not applicable.
aP value < 0.05.
confirming that the clinical manifestations of chronic
transplant glomerulopathy tend to develop late after
transplantation [3]. At the time of diagnosis, patients
with chronic transplant glomerulopathy had a simi-
lar degree of renal dysfunction, but on average the
serum albumin level was lower and proteinuria more se-
vere than patients with chronic allograft nephropathy,
compatible with glomerular injury. We documented an
increased systolic blood pressure and use of antihyper-
tensive drugs in patients with chronic transplant glomeru-
lopathy. However, more chronic transplant glomerulopa-
thy patients used cyclosporine (Neoral) at time of biopsy,
an agent with increased bioavailability that accounted
for increased blood pressure and proteinuria after con-
version from Sandimmune in the Leiden cohort of renal
transplants [14].
Double GBM contours are a key light microscopic
feature of chronic transplant glomerulopathy and were
required for the diagnosis of chronic transplant glomeru-
lopathy in our study. We observed in all but one patient
a variable degree of glomerulitis in the glomerular tuft,
a feature characteristic of acute transplant glomerulitis
[4, 16]. We confirm earlier results from our center and
from others that chronic vascular changes did not paral-
lel chronic transplant glomerulopathy [3, 19]. Ten patients
showed no or minor obliteration of the arterial lumen, in-
dicating that ischemia is not a likely mechanism responsi-
ble for chronic transplant glomerulopathy. The observed
chronic tubulointerstitial changes are most likely related
to previous acute rejection episodes [20].
Late acute transplant glomerulitis, observed in four pa-
tients, occurred earlier than chronic transplant glomeru-
lopathy and was associated with severe proteinuria and
subsequent rapid graft failure. Messias et al [16] examined
early glomerulitis, that occurred in 28/63 (44%) patients
with acute rejection within 3 months. Due to a strong
association with vascular rejection there was no indepen-
dent effect on graft survival [16]. In our opinion, early
glomerulitis at time of an acute rejection episode should
be distinguished from late onset transplant glomerulitis.
Assessment of risk factors revealed that both
chronic transplant glomerulopathy and chronic allograft
nephropathy were strongly related with pretransplant
sensitization and late acute rejection episodes, suggest-
ing chronic rejection. These factors were also present in
patients with acute transplant glomerulitis. In the study
of Messias et al [16], a significantly higher percentage
of patients in the early glomerulitis group was highly
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Table 4. Prognostic factors of graft failure from chronic transplant glomerulopathy (CTG) and chronic allograft nephropathy (CAN)
CTG (N = 18) CAN (N = 108)
RR 95% CI RR 95% CI
Time since transplantation years 0.71 0.51–0.98a 0.97 0.89–1.07
New immunosuppressive agents 0.48 0.12–1.94 1.07 0.51–2.22
Serum creatinine 10 lmol/L 1.15 1.04–1.29a 1.05 1.03–1.08a
Endogenous creatinine clearance 10 mL/min 0.41 0.16–1.06 0.74 0.61–0.89a
Serum albumin g/L 0.82 0.70–0.97a 0.94 0.89–0.99a
Proteinuria g/24 hours 1.29 1.01–1.64a 1.32 1.19–1.48a
Minimum proteinuria g/24 hours 1.45 1.08–1.95a 1.77 1.46–2.15a
Systolic blood pressure 10 mm Hg 1.08 0.63–1.88 1.15 1.01–1.29a
Systolic blood pressure at minimum proteinuria 10 mm Hg 1.24 0.84–1.82 1.40 1.23–1.60a
Diastolic blood pressure 10 mm Hg 0.67 0.36–1.27 1.17 1.01–1.34a
Diastolic blood pressure at mininum proteinuria 10 mm Hg 2.14 0.94–4.89 1.38 1.08–1.77a
aP value < 0.05.
sensitized pretransplantation, had retransplants and had
delayed graft function compared to the nonglomeruli-
tis group. Preformed anti-HLA antibodies are related
to acute humoral rejection and also increase the risk
of chronic allograft nephropathy [21, 22]. In comparison
with transplants with stable function both chronic trans-
plant glomerulopathy and chronic allograft nephropa-
thy were associated with late acute rejection episodes.
We found earlier that acute rejection episodes beyond
3 months have a detrimental impact on long-term out-
come and are associated with CREG mismatches [17, 23].
At this time posttransplantation, indirect allorecognition
(i.e., activation of T helper cells by donor MHC molecules
presented by recipient antigen presenting cells) may
trigger the production of antibodies that may mediate
chronic rejection [11, 24]. Therefore, both preexisting
and newly formed antibodies posttransplantation may
increase the risk of chronic allograft nephropathy and
chronic transplant glomerulopathy.
Because of this risk profile of chronic transplant
glomerulopathy, we decided to investigate C4d deposi-
tion in the transplants. We used a polyclonal anti-C4d
antibody suitable for detection of glomerular C4d on
paraffin sections [12, 13]. Glomerular deposits of C4d
were present in 10/11 biopsies with chronic transplant
glomerulopathy and in 3/3 cases showing acute transplant
glomerulitis. Peritubular staining for C4d was positive in
respectively 4/10 and 3/3 cases with glomerular C4d de-
posits. Absence of glomerular C4d staining in all but one
tested patients with chronic allograft nephropathy sug-
gest that this antibody might be useful in characterizing
late transplant glomerulopathy. Endothelial deposition
of the complement split product C4d in peritubular cap-
illaries has been established as a marker for both acute
and chronic humoral rejection defined by the presence of
antidonor HLA antibodies [9]. Absence of concomitant
capillary immunoglobulin staining in C4d-positive biop-
sies has been explained by less covalent binding com-
pared to C4d [9]. Recently, C4d deposition in peritubular
capillaries was detected on paraffin sections in 34% of
213 late biopsies and found to be associated with tubu-
lar basement membrane multilayering and chronic trans-
plant glomerulopathy [12]. However, in contrast to our
data, glomerular C4d staining was observed in only 12%
of the chronic transplant glomerulopathy biopsies, which
is difficult to explain unless their criteria for the diagnosis
of chronic transplant glomerulopathy were less strict [12].
In biopsies with unaffected glomeruli but positive C4d
in peritubular capillaries, progression to chronic trans-
plant glomerulopathy could be observed in follow-up
biopsies [12]. Ongoing humoral rejection may link early
glomerulitis and late transplant glomerulopathy. How-
ever the acute transplant glomerulitis cases presented
in this study were all rapidly progressive and did not
progress into chronic transplant glomerulopathy suggest-
ing that acute transplant glomerulitis not necessarily re-
sults in chronic transplant glomerulopathy.
The evidence for humoral rejection in late transplant
glomerulopathy suggests that antibodies directed against
donor HLA antigens play a role. In a series of chronic
humoral rejection, 15 out of 17 patients with C4d in the
peritubular capillaries had antidonor HLA antibodies
[11]. We could detect antidonor HLA antibodies in 3/10
chronic transplant glomerulopathy cases with glomerular
C4d deposits, suggesting that a tissue-specific response
might also be involved. However, we cannot exclude that
the levels of circulating anti-HLA antibodies are unde-
tectable due to absorption by antigens in the graft. In
an experimental model, we found circulating and kid-
ney graft bound IgG antibodies against the GBM in rats
with chronic transplant glomerulopathy. Using proteomic
techniques the heparan sulfate proteoglycan perlecan
and the a1 chain of collagen VI in association with the a5
chain of collagen IV were identified as the antigens recog-
nized by the antibodies [25]. We hypothesize that similar
responses against glomerular antigens are also present in
patients with transplant glomerulopathy.
Humoral rejection warrants a specific therapeutic strat-
egy. In chronic rejection decrease of antidonor HLA an-
tibodies and C4d deposition can be induced by rescue
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therapy with tacrolimus and mycophenolate mofetil [26].
Furthermore, patients who stay on mycophenolate for a
prolonged period of time have a lower risk of late acute
rejection episodes and chronic allograft nephropathy [27,
28]. In our series, only one patient with chronic transplant
glomerulopathy, remarkably the subject without C4d de-
posits, used mycophenolate mofetil at time of diagno-
sis. As this agent was only introduced in our center in
1997, longer follow-up is needed to determine whether
this agent might reduce the incidence of chronic trans-
plant glomerulopathy as well.
The prognosis of chronic transplant glomerulopathy
was related to the time of diagnosis and level of pro-
teinuria. However, once the diagnosis has been made we
found a similar graft survival rate compared to patients
with earlier diagnosed chronic allograft nephropathy. In
both groups outcome correlated with proteinuria, in the
chronic allograft nephropathy group together with con-
comitant systolic blood pressure and renal function at
time of diagnosis. These results support recent evidence
that renoprotection could be achieved when long-lasting
angiotensin-converting enzyme (ACE) inhibition results
in persistent reduction in proteinuria [29, 30]. ACE in-
hibitors and angiotensin II antagonists are well tolerated
in transplant recipients with chronic allograft nephropa-
thy and are associated with stabilization of renal function
[31, 32].
CONCLUSION
Chronic transplant glomerulopathy may present years
after transplantation. Sensitization and late acute re-
jection episodes were identified as risk factors strongly
suggesting an underlying immunologic mechanism. The
presence of glomerular C4d deposits supports a role
for humoral immune responses in the pathogenesis of
chronic transplant glomerulopathy.
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